Clinical Trials Browser

Vinorelbine × 30 days × Clear all

NCT02567435 2026-05-27

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

Phase 3 Active not recruiting

325 enrolled 14 charts

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

NCT06459180 2026-05-27

TroFuse-020

Phase 3 Active not recruiting

Uterine Cervical Neoplasms

NCT04296162 2026-05-26

ORCHID

Phase 2 Completed

Breast Neoplasms

NCT07461454 2026-05-26

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

Phase 3 Recruiting

Breast Neoplasms

NCT06564844 2026-05-22

TROPION-Lung12

Phase 3 Active not recruiting

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT04145349 2026-05-11

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

Phase 1/2 Completed

30 enrolled 16 charts

Sarcoma, Desmoplastic Small Round Cell Tumor

NCT05347134 2026-05-08

SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Phase 3 Active not recruiting

Triple Negative Breast Neoplasms

NCT06081959 2026-05-08

Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer

Phase 3 Recruiting

Breast Neoplasms

NCT06632327 2026-05-08

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

Phase 3 Recruiting

Lung Neoplasms

NCT03456076 2026-05-05

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

Phase 3 Active not recruiting

257 enrolled 14 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04994132 2026-05-05

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

Phase 3 Active not recruiting

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

NCT05104866 2026-05-05

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

Phase 3 Active not recruiting

732 enrolled 22 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis